Notch receptor family (NOTCH)

The Notch receptor family consists of four highly conserved single-pass transmembrane receptors (Notch 1-4) that play a critical role in cell fate determination, proliferation, and differentiation through juxtacrine signaling. Upon binding to ligands of the Delta-like or Jagged families on adjacent cells, the receptors undergo sequential proteolytic cleavages, the last of which is mediated by the gamma-secretase complex (Source: UniProt, P46531). This release of the Notch intracellular domain (NICD) allows it to translocate to the nucleus, where it acts as a transcriptional activator for target genes such as HES and HEY. Dysregulation of Notch signaling is implicated in various pathologies, most notably in T-cell acute lymphoblastic leukemia (T-ALL) and several solid tumors, where it often promotes an undifferentiated, proliferative state (Source: NIH, Cancer.gov). Therapeutic strategies include gamma-secretase inhibitors (GSIs) and monoclonal antibodies, though clinical utility has been limited by significant off-target toxicities, particularly in the gastrointestinal tract due to the role of Notch in maintaining intestinal stem cell homeostasis (Source: PubMed, PMC3541339).

Other names

Notch signaling receptorsNeurogenic locus notch homolog protein familyhNotch

Drugs targeting the Notch family primarily function by inhibiting the proteolytic cleavage of the receptors. Gamma-secretase inhibitors (GSIs) prevent the release of the Notch intracellular domain (NICD), thereby blocking its translocation to the nucleus and subsequent transcriptional activation. Monoclonal antibodies target specific Notch receptors or their ligands (e.g., DLL4) to prevent receptor-ligand interaction and downstream signaling (Source: PubMed, PMC4747376; StatPearls, NBK537200).